Therefore, DPP-4 inhibitors may be useful in the management of hyperglycemia in patients with glucocorticoids-induced diabetes, which is characterized by normal or mild increase in fasting plasma glucose levels and a remarkable increase in postprandial glucose levels. The gene discussed is DPP4; the disease is diabetes mellitus.